Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report

The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical case reports 2024-02, Vol.18 (1), p.57-57, Article 57
Main Authors: Dierckx, Stéphanie, Nisolle, Jean-François, Boutsen, Yves
Format: Article
Language:English
Subjects:
Acne
Anti-inflammatory agents
Arthritis
Bisphosphonates
Blood tests
Case report
Case reports
Disodium pamidronate
Exostosis
JAK-inhibitors
Kinases
Magnetic resonance imaging
Nonsteroidal anti-inflammatory drugs
Patients
Pelvis
Pulmonary embolism
Reimbursement
Rheumatic diseases
Sacroiliitis
SAPHO syndrome
Skin
Sulfasalazine
Synovitis
TNF inhibitors
Tofacitinib
Tomography
Tumor necrosis factor-TNF
Vertebrae
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c459t-85a4c0c316a71ca60a36120c7eb6b7ec5263f231fad6f0f4717a08e1ac80440e3
container_end_page 57
container_issue 1
container_start_page 57
container_title Journal of medical case reports
container_volume 18
creator Dierckx, Stéphanie
Nisolle, Jean-François
Boutsen, Yves
description The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She had been treated with sulfasalazine and anti-inflammatory drugs for many years without any success. A few weeks after starting treatment with tofacitinib, both clinical and biological parameters dramatically improved. Imaging also showed considerable regression of the vertebral and pelvic lesions. However, tofacitinib had to be discontinued due to the occurrence of pulmonary embolism. Consequently, recurrence of bone pain and biologic inflammation was rapidly observed. Anti-JAKs are an interesting treatment option in the management of SAPHO syndrome that need further clinical trials and assessment for validating response.
doi_str_mv 10.1186/s13256-024-04366-w
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6fd3f2f782354eada3a0f1abce1495de</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A782720365</galeid><doaj_id>oai_doaj_org_article_6fd3f2f782354eada3a0f1abce1495de</doaj_id><sourcerecordid>A782720365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-85a4c0c316a71ca60a36120c7eb6b7ec5263f231fad6f0f4717a08e1ac80440e3</originalsourceid><addsrcrecordid>eNptUstu1TAQjRCIlsIPsECW2LBoil9xHHZVoVCpEhtYWxNn3PoqiYOdtLorfh2nactDyJbsGZ1zZsY-RfGa0RPGtHqfmOCVKimXJZVCqfL2SXHI6oqXrJH10z_uB8WLlHaUVko34nlxILRQVDN1WPz8GGGA2VsSMU1hTEiCI2k_hhs_-3RMwI54TKYlzUsf0pq53k8YQ5q3CMaO5ABX9MrrYhiQzCFvBzZnR9-SIYxhvsYI0_4DAWIhl4k4hTi_LJ456BO-uj-Piu_nn76dfSkvv36-ODu9LK2smrnUFUhLrWAKamZBURCKcWprbFVbo624Eo4L5qBTjjpZsxqoRgZWUykpiqPiYtPtAuzMFP0AcW8CeHOXCPHKQMzP0KNRrstartZcVBKhAwHUMWgtMtlU3ar1btOaYvixYJrN4JPFvocRw5IMb7jmkilJM_TtP9BdWOKYJ82o_Bt1o6T-jbqCXN-PLswR7CpqTnMbNadCVRl18h9UXh0O3oYRnc_5vwh8I9j8XSmie5ybUbM6yGwOMtlB5s5B5jaT3tx3vLQDdo-UB8uIX6q_wg8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956879648</pqid></control><display><type>article</type><title>Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Dierckx, Stéphanie ; Nisolle, Jean-François ; Boutsen, Yves</creator><creatorcontrib>Dierckx, Stéphanie ; Nisolle, Jean-François ; Boutsen, Yves</creatorcontrib><description>The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She had been treated with sulfasalazine and anti-inflammatory drugs for many years without any success. A few weeks after starting treatment with tofacitinib, both clinical and biological parameters dramatically improved. Imaging also showed considerable regression of the vertebral and pelvic lesions. However, tofacitinib had to be discontinued due to the occurrence of pulmonary embolism. Consequently, recurrence of bone pain and biologic inflammation was rapidly observed. Anti-JAKs are an interesting treatment option in the management of SAPHO syndrome that need further clinical trials and assessment for validating response.</description><identifier>ISSN: 1752-1947</identifier><identifier>EISSN: 1752-1947</identifier><identifier>DOI: 10.1186/s13256-024-04366-w</identifier><identifier>PMID: 38360816</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acne ; Anti-inflammatory agents ; Arthritis ; Bisphosphonates ; Blood tests ; Case report ; Case reports ; Disodium pamidronate ; Exostosis ; JAK-inhibitors ; Kinases ; Magnetic resonance imaging ; Nonsteroidal anti-inflammatory drugs ; Patients ; Pelvis ; Pulmonary embolism ; Reimbursement ; Rheumatic diseases ; Sacroiliitis ; SAPHO syndrome ; Skin ; Sulfasalazine ; Synovitis ; TNF inhibitors ; Tofacitinib ; Tomography ; Tumor necrosis factor-TNF ; Vertebrae</subject><ispartof>Journal of medical case reports, 2024-02, Vol.18 (1), p.57-57, Article 57</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c459t-85a4c0c316a71ca60a36120c7eb6b7ec5263f231fad6f0f4717a08e1ac80440e3</cites><orcidid>0000-0002-9062-679X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2956879648?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25732,27903,27904,36991,36992,44569</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38360816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dierckx, Stéphanie</creatorcontrib><creatorcontrib>Nisolle, Jean-François</creatorcontrib><creatorcontrib>Boutsen, Yves</creatorcontrib><title>Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report</title><title>Journal of medical case reports</title><addtitle>J Med Case Rep</addtitle><description>The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She had been treated with sulfasalazine and anti-inflammatory drugs for many years without any success. A few weeks after starting treatment with tofacitinib, both clinical and biological parameters dramatically improved. Imaging also showed considerable regression of the vertebral and pelvic lesions. However, tofacitinib had to be discontinued due to the occurrence of pulmonary embolism. Consequently, recurrence of bone pain and biologic inflammation was rapidly observed. Anti-JAKs are an interesting treatment option in the management of SAPHO syndrome that need further clinical trials and assessment for validating response.</description><subject>Acne</subject><subject>Anti-inflammatory agents</subject><subject>Arthritis</subject><subject>Bisphosphonates</subject><subject>Blood tests</subject><subject>Case report</subject><subject>Case reports</subject><subject>Disodium pamidronate</subject><subject>Exostosis</subject><subject>JAK-inhibitors</subject><subject>Kinases</subject><subject>Magnetic resonance imaging</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Pulmonary embolism</subject><subject>Reimbursement</subject><subject>Rheumatic diseases</subject><subject>Sacroiliitis</subject><subject>SAPHO syndrome</subject><subject>Skin</subject><subject>Sulfasalazine</subject><subject>Synovitis</subject><subject>TNF inhibitors</subject><subject>Tofacitinib</subject><subject>Tomography</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vertebrae</subject><issn>1752-1947</issn><issn>1752-1947</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUstu1TAQjRCIlsIPsECW2LBoil9xHHZVoVCpEhtYWxNn3PoqiYOdtLorfh2nactDyJbsGZ1zZsY-RfGa0RPGtHqfmOCVKimXJZVCqfL2SXHI6oqXrJH10z_uB8WLlHaUVko34nlxILRQVDN1WPz8GGGA2VsSMU1hTEiCI2k_hhs_-3RMwI54TKYlzUsf0pq53k8YQ5q3CMaO5ABX9MrrYhiQzCFvBzZnR9-SIYxhvsYI0_4DAWIhl4k4hTi_LJ456BO-uj-Piu_nn76dfSkvv36-ODu9LK2smrnUFUhLrWAKamZBURCKcWprbFVbo624Eo4L5qBTjjpZsxqoRgZWUykpiqPiYtPtAuzMFP0AcW8CeHOXCPHKQMzP0KNRrstartZcVBKhAwHUMWgtMtlU3ar1btOaYvixYJrN4JPFvocRw5IMb7jmkilJM_TtP9BdWOKYJ82o_Bt1o6T-jbqCXN-PLswR7CpqTnMbNadCVRl18h9UXh0O3oYRnc_5vwh8I9j8XSmie5ybUbM6yGwOMtlB5s5B5jaT3tx3vLQDdo-UB8uIX6q_wg8</recordid><startdate>20240216</startdate><enddate>20240216</enddate><creator>Dierckx, Stéphanie</creator><creator>Nisolle, Jean-François</creator><creator>Boutsen, Yves</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9062-679X</orcidid></search><sort><creationdate>20240216</creationdate><title>Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report</title><author>Dierckx, Stéphanie ; Nisolle, Jean-François ; Boutsen, Yves</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-85a4c0c316a71ca60a36120c7eb6b7ec5263f231fad6f0f4717a08e1ac80440e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acne</topic><topic>Anti-inflammatory agents</topic><topic>Arthritis</topic><topic>Bisphosphonates</topic><topic>Blood tests</topic><topic>Case report</topic><topic>Case reports</topic><topic>Disodium pamidronate</topic><topic>Exostosis</topic><topic>JAK-inhibitors</topic><topic>Kinases</topic><topic>Magnetic resonance imaging</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Pulmonary embolism</topic><topic>Reimbursement</topic><topic>Rheumatic diseases</topic><topic>Sacroiliitis</topic><topic>SAPHO syndrome</topic><topic>Skin</topic><topic>Sulfasalazine</topic><topic>Synovitis</topic><topic>TNF inhibitors</topic><topic>Tofacitinib</topic><topic>Tomography</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vertebrae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dierckx, Stéphanie</creatorcontrib><creatorcontrib>Nisolle, Jean-François</creatorcontrib><creatorcontrib>Boutsen, Yves</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of medical case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dierckx, Stéphanie</au><au>Nisolle, Jean-François</au><au>Boutsen, Yves</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report</atitle><jtitle>Journal of medical case reports</jtitle><addtitle>J Med Case Rep</addtitle><date>2024-02-16</date><risdate>2024</risdate><volume>18</volume><issue>1</issue><spage>57</spage><epage>57</epage><pages>57-57</pages><artnum>57</artnum><issn>1752-1947</issn><eissn>1752-1947</eissn><abstract>The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She had been treated with sulfasalazine and anti-inflammatory drugs for many years without any success. A few weeks after starting treatment with tofacitinib, both clinical and biological parameters dramatically improved. Imaging also showed considerable regression of the vertebral and pelvic lesions. However, tofacitinib had to be discontinued due to the occurrence of pulmonary embolism. Consequently, recurrence of bone pain and biologic inflammation was rapidly observed. Anti-JAKs are an interesting treatment option in the management of SAPHO syndrome that need further clinical trials and assessment for validating response.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38360816</pmid><doi>10.1186/s13256-024-04366-w</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9062-679X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1752-1947
ispartof Journal of medical case reports, 2024-02, Vol.18 (1), p.57-57, Article 57
issn 1752-1947
1752-1947
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6fd3f2f782354eada3a0f1abce1495de
source Open Access: PubMed Central; Publicly Available Content Database
subjects Acne
Anti-inflammatory agents
Arthritis
Bisphosphonates
Blood tests
Case report
Case reports
Disodium pamidronate
Exostosis
JAK-inhibitors
Kinases
Magnetic resonance imaging
Nonsteroidal anti-inflammatory drugs
Patients
Pelvis
Pulmonary embolism
Reimbursement
Rheumatic diseases
Sacroiliitis
SAPHO syndrome
Skin
Sulfasalazine
Synovitis
TNF inhibitors
Tofacitinib
Tomography
Tumor necrosis factor-TNF
Vertebrae
title Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A22%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dramatic%20response%20of%20synovitis,%20acne,%20pustulosis,%20hyperostosis,%20and%20osteitis%20syndrome%20to%20tofacitinib%20monotherapy:%20a%20case%20report&rft.jtitle=Journal%20of%20medical%20case%20reports&rft.au=Dierckx,%20St%C3%A9phanie&rft.date=2024-02-16&rft.volume=18&rft.issue=1&rft.spage=57&rft.epage=57&rft.pages=57-57&rft.artnum=57&rft.issn=1752-1947&rft.eissn=1752-1947&rft_id=info:doi/10.1186/s13256-024-04366-w&rft_dat=%3Cgale_doaj_%3EA782720365%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-85a4c0c316a71ca60a36120c7eb6b7ec5263f231fad6f0f4717a08e1ac80440e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956879648&rft_id=info:pmid/38360816&rft_galeid=A782720365&rfr_iscdi=true